Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave Acetate Safety and Efficacy in Open-Angle Glaucoma or Ocular Hypertension
NCT00691717Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jun 2008
- Primary completion
- Sep 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anecortave in open-angle glaucoma (OAG) and ocular hypertension (4 arms), sponsored by Alcon Inc. Primary endpoint: Mean Intraocular Pressure at 8 am at 6 months. Started Jun 2008; status: completed.
02
Drugs
anecortave
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00691717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00691717.